Controlling complexity: The clinical relevance of mouse complex genetics

European Journal of Human Genetics

Volumn 21, Issue 11, 2013, Pages 1191-1196

  Schughart, Klaus ^a,b,c   Libert, Claude ^d,e   Kas, Martien J ^f  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^b UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^e GHENT UNIVERSITY   (Belgium)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

forward genetics; Mouse model; review

Indexed keywords

OREXIN; TOLL LIKE RECEPTOR 4;

ANIMAL GENETICS; ANXIETY DISORDER; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; AVOIDANCE BEHAVIOR; BIPOLAR DISORDER; CARDIOVASCULAR DISEASE; CHROMOSOME SUBSTITUTION STRAIN; CIRCADIAN RHYTHM; CLINICAL MEDICINE; CORPUS CALLOSUM; DIABETES MELLITUS; EXPERIMENTAL MOUSE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HYPERTENSION; IMMUNE RESPONSE; IMMUNITY; INBRED MOUSE STRAIN; INBRED STRAIN; ISCHEMIA; MEDICAL RESEARCH; METABOLOMICS; MOUSE; MOUSE MODEL; MOUSE MUTANT; NARCOLEPSY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; REVERSE GENETICS; REVIEW;

ANIMALIA;

ANIMALS; BIOMEDICAL RESEARCH; HUMANS; MICE; MODELS, ANIMAL; REVERSE GENETICS;

EID: 84885896174     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2013.79     Document Type: Review

References (74)

1. Seok J, Warren HS, Cuenca AG et al: Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2013; 110: 3507-3512.
2. Schughart K: SYSGENET: a meeting report from a new European network for systems genetics. Mamm Genome 2010; 21: 331-336.
3. Snell GD: Studies in histocompatibility. Science 1981; 213: 172-178. (Pubitemid 11060563)
4. Kohler G, Howe SC, Milstein C: Fusion between immunoglobulin-secreting and nonsecreting myeloma cell lines. Eur J Immunol 1976; 6: 292-295.
5. Kohler G, Milstein C: Derivation of specific antibodyproducing tissue culture and tumor lines by cell fusion. Eur J Immunol 1976; 6: 511-519.
6. Peirce JL, Lu L, Gu J, Silver LM, Williams RW: A new set of BXD recombinant inbred lines from advanced intercross populations in mice. BMC Genet 2004; 5: 7.
7. Taylor BA, Wnek C, Kotlus BS, Roeme rN, MacTaggart T, Phillips SJ: Genotyping new BXD recombinant inbred mouse strains and comparison of BXD and consensus maps. Mamm Genome 1999; 10: 335-348. (Pubitemid 29390484)
8. Collaborative Cross Consortium. The genome architecture of the collaborative cross mouse genetic reference population. Genetics 2012; 190: 389-401.
9. Kelada SN, Aylor DL, Peck BC et al: Genetic analysis of hematological parameters in incipient lines of the collaborative cross. G3 (Bethesda) 2012; 2: 157-165.
10. Bottomly D, Ferris MT, Aicher LD et al: Expression quantitative trait loci for extreme host response to influenza a in pre-collaborative cross mice. G3 (Bethesda) 2012; 2: 213-221.
11. Aylor DL, Valdar W, Foulds-Mathes W et al: Genetic analysis of complex traits in the emerging Collaborative Cross. Genome Res 2011; 21: 1213-1222.
12. Durrant C, Tayem H, Yalcin B et al: Collaborative Cross mice and their power to map host susceptibility to Aspergillus fumigatus infection. Genome Res 2011; 21: 1239-1248.
13. Philip VM, Sokoloff G, Ackert-Bicknell CL et al: Genetic analysis in the Collaborative Cross breeding population. Genome Res 2011; 21: 1223-1238.
14. Nolan PM, Hugill A, Cox RD: ENU mutagenesis in the mouse: application to human genetic disease. Brief Funct Genomic Proteomic 2002; 1: 278-289.
15. Cox RD, Brown SD: Rodent models of genetic disease. Curr Opin Genet Dev 2003; 13: 278-283. (Pubitemid 36645091)
16. Beier DR, Herron BJ: Genetic mapping and ENU mutagenesis. Genetica 2004; 122: 65-69.
17. Clark AT, Goldowitz D, Takahashi JS et al: Implementing large-scale ENU mutagenesis screens in North America. Genetica 2004; 122: 51-64. (Pubitemid 39459524)
18. Sung YH, Song J, Lee HW: Functional genomics approach using mice. J Biochem Mol Biol 2004; 37: 122-132. (Pubitemid 38402580)
19. Acevedo-Arozena A, Wells S, Potter P, Kelly M, Cox RD, Brown SD: ENU mutagenesis, a way forward to understand gene function. Annu Rev Genomics Hum Genet 2008; 9: 49-69.
20. Gondo Y, Fukumura R, Murata T, Makino S: ENUbased gene-driven mutagenesis in the mouse: a nextgeneration gene-targeting system. Exp Anim 2010; 59: 537-548.
21. Fuchs H, Gailus-Durner V, Adler T et al: Mouse phenotyping. Methods 2011; 53: 120-135.
22. Nguyen N, Judd LM, Kalantzis A, Whittle B, Giraud AS, van Driel IR: Random mutagenesis of the mouse genome: a strategy for discovering gene function and the molecular basis of disease. Am J Physiol Gastrointest Liver Physiol 2011; 300: G1-11.
23. Freudenberg MA, Keppler D, Galanos C: Requirement for lipopolysaccharide-responsive macrophages in galactosamine-induced sensitization to endotoxin. Infect Immun 1986; 51: 891-895. (Pubitemid 16162992)
24. Poltorak A, Smirnova I, He X et al: Genetic and physical mapping of the Lps locus: identification of the toll-4 receptor as a candidate gene in the critical region. Blood Cells Mol Dis 1998; 24: 340-355. (Pubitemid 28524834)
25. Cohen J: The immunopathogenesis of sepsis. Nature 2002; 420: 885-891. (Pubitemid 36019643)
26. Tanga FY, Nutile-McMenemy N, DeLeo JA: The CNS role of Toll-like receptor 4 in innate neuroimmunity and painful neuropathy. Proc Natl Acad Sci USA 2005; 102: 5856-5861. (Pubitemid 40559649)
27. O'Neill LA, Bryant CE, Doyle SL: Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev 2009; 61: 177-197.
28. Beutler B, Goodnow CC: How host defense is encoded in the mammalian genome. Mamm Genome 2011; 22: 1-5.
29. Mashimo T, Lucas M, Simon-Chazottes D et al: A nonsense mutation in the gene encoding 2'-5'-oligoadenylate synthetase/L1 isoform is associated with West Nile virus susceptibility in laboratory mice. Proc Natl Acad Sci USA 2002; 99: 11311-11316. (Pubitemid 34920922)
30. Perelygin AA, Scherbik SV, Zhulin IB, Stockman BM, Li Y, Brinton MA: Positional cloning of the murine flavivirus resistance gene. Proc Natl Acad Sci USA 2002; 99: 9322-9327. (Pubitemid 34764612)
31. Scherbik SV, Stockman BM, Brinton MA: Differential expression of interferon (IFN) regulatory factors and IFN-stimulated genes at early times after West Nile virus infection of mouse embryo fibroblasts. J Virol 2007; 81: 12005-12018. (Pubitemid 47623831)
32. Simon-Chazottes D, Frenkiel MP, Montagutelli X, Guenet JL, Despres P, Panthier JJ: Transgenic expression of full-length 2',5'-oligoadenylate synthetase 1b confers to BALB/c mice resistance against West Nile virus-induced encephalitis. Virology 2011; 417: 147-153.
33. Yakub I, Lillibridge KM, Moran A et al: Single nucleotide polymorphisms in genes for 2'-5'-oligoadenylate synthetase and RNase L inpatients hospitalized with West Nile virus infection. J Infect Dis 2005; 192: 1741-1748. (Pubitemid 41587824)
34. Lim JK, Lisco A, McDermott DH et al: Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathog 2009; 5: e1000321.
35. Barr J, Vazquez-Chantada M, Alonso C et al: Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease. J Proteome Res 2010; 9: 4501-4512.
36. Friedman JM, Halaas JL: Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-770. (Pubitemid 28485436)
37. Montague CT, Farooqi IS, Whitehead JP et al: Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997; 387: 903-908. (Pubitemid 27289591)
38. Farooqi IS, Jebb SA, Langmack G et al: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999; 341: 879-884. (Pubitemid 29427050)
39. Farooqi IS, Matarese G, Lord GM et al: Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002; 110: 1093-1103. (Pubitemid 35215890)
40. Koutnikova H, Laakso M, Lu L et al: Identification of the UBP1 locus as a critical blood pressure determinant using a combination of mouse and human genetics. PLoS Genet 2009; 5: e1000591.
41. Chen Y, Rollins J, Paigen B, Wang X: Genetic and genomic insights into the molecular basis of atherosclerosis. Cell Metab 2007; 6: 164-179. (Pubitemid 47324136)
42. Wang X, Ria M, Kelmenson PM et al: Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. Nat Genet 2005; 37: 365-372.
43. Vitaterna MH, King DP, Chang AM et al: Mutagenesis and mapping of a mouse gene, Clock, essential for circadian behavior. Science 1994; 264: 719-725. (Pubitemid 24185884)
44. Antoch MP, Song EJ, Chang AM et al: Functional identification of the mouse circadian Clock gene by transgenic BAC rescue. Cell 1997; 89: 655-667. (Pubitemid 27511775)
45. King DP, Zhao Y, Sangoram AM et al: Positional cloning of the mouse circadian clock gene. Cell 1997; 89: 641-653. (Pubitemid 27511774)
46. Toh KL, Jones CR, He Y et al: An hPer2 phosphorylation site mutation in familial advanced sleep phase syndrome. Science 2001; 291: 1040-1043. (Pubitemid 32157412)
47. Xu Y, Padiath QS, Shapiro RE et al: Functional consequences of a CKIdelta mutation causing familial advanced sleep phase syndrome. Nature 2005; 434: 640-644. (Pubitemid 40488555)
48. Huang W, Ramsey KM, Marcheva B, Bass J: Circadian rhythms, sleep, and metabolism. J Clin Invest 2011; 121: 2133-2141.
49. Yu EA, Weaver DR: Disrupting the circadian clock: gene-specific effects on aging, cancer, and other phenotypes. Aging (Albany NY) 2011; 3: 479-493.
50. Poot M, Badea A, Williams RW, Kas MJ: Identifying human disease genes through cross-species gene mapping of evolutionary conserved processes. PLoS ONE 2011; 6: e18612.
51. Chemelli RM, Willie JT, Sinton CM et al: Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999; 98: 437-451. (Pubitemid 29402482)
52. Lin L, Faraco J, Li R et al: The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999; 98: 365-376. (Pubitemid 29380571)
53. Peyron C, Faraco J, Rogers W et al: A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000; 6: 991-997.
54. Kornum BR, Faraco J, Mignot E: Narcolepsy with hypocretin/orexin deficiency, infections and autoimmunity of the brain. Curr Opin Neurobiol 2011; 21: 897-903.
55. Kas MJ, Kahn RS, Collier DA et al: Translational neuroscience of Schizophrenia: seeking a meeting of minds between mouse and man. Sci Transl Med 2011; 3: 102mr103.
56. de Mooij-van Malsen AJ, van Lith HA, Oppelaar H et al: Interspecies trait genetics reveals association of Adcy8 with mouse avoidance behavior and a human mood disorder. Biol Psychiatry 2009; 66: 1123-1130.
57. Singer JB, Hill AE, Burrage LC et al: Genetic dissection of complex traits with chromosome substitution strains of mice. Science 2004; 304: 445-448. (Pubitemid 38495941)
58. Hovatta I, Tennant RS, Helton R et al: Glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice. Nature 2005; 438: 662-666. (Pubitemid 41740575)
59. Donner J, Pirkola S, Silander K et al: An association analysis of murine anxiety genes in humans implicates novel candidate genes for anxiety disorders. Biol Psychiatry 2008; 64: 672-680.
60. Malki K, Uher R, Paya-Cano J et al: Convergent animal and human evidence suggests a role of PPM1A gene in response to antidepressants. Biol Psychiatry 2011; 69: 360-365.
61. Rosenthal N, Brown S: The mouse ascending: perspectives for human-disease models. Nat Cell Biol 2007; 9: 993-999. (Pubitemid 47338136)
62. Masih-ul A, Mü ller W: Studying immunology in mice; in Hedrich H (eds). The Laboratory Mouse. London, UK: Academic Press, 2012; pp 349-362.
63. Brown SD, Moore MW: Towards an encyclopaedia of mammalian gene function: the International Mouse Phenotyping Consortium. Dis Model Mech 2012; 5: 289-292.
64. Coleman DL: Diabetes-obesity syndromes in mice. Diabetes 1982; 31: 1-6. (Pubitemid 12128678)
65. Ishihara H, Takeda S, Tamura A et al: Disruption of the WFS1 gene in mice causes progressive betacell loss and impaired stimulus-secretion coupling in insulin secretion. Hum Mol Genet 2004; 13: 1159-1170. (Pubitemid 38786998)
66. Shimomura K, Lowrey PL, Vitaterna MH et al: Genetic suppression of the circadian Clock mutation by the melatonin biosynthesis pathway. Proc Natl Acad Sci USA 2010; 107: 8399-8403.
67. Seok J, Warren HS, Cuenca AG et al: Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2013; 110: 3507-3512.
68. Zambrowicz BP, Turner CA, Sands AT: Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry. Curr Opin Pharmacol 2003; 3: 563-570. (Pubitemid 37221139)
69. Zambrowicz BP, Sands AT: Knockouts model the 100 best-selling drugs-will they model the next 100? Nat Rev Drug Discov 2003; 2: 38-51. (Pubitemid 37361623)
70. Hackam DG, Redelmeier DA: Translation of research evidence from animals to humans. JAMA 2006; 296: 1731-1732. (Pubitemid 44547792)
71. van der Worp HB, Howells DW, Sena ES et al: Can animal models of disease reliably inform human studies? PLoS Med 2010; 7: e1000245.
72. Baldarelli RM: Drug discovery: in defence of the animal model. Nature 2012; 485: 309.
73. Aitman TJ, Boone C, Churchill GA, Hengartner MO, Mackay TF, Stemple DL: The future of model organisms in human disease research. Nat Rev Genet 2011; 12: 575-582.
74. Hans J: Delphi-Methode; in Harting JM, Kerstan T (eds). Wissen to go. Ein Studium generale in 100 Begriffen. München, Germany: Piper, 2008.